211 related articles for article (PubMed ID: 30056926)
1. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
[TBL] [Abstract][Full Text] [Related]
2. Living Donor Preemptive Kidney Transplantation in Tuberous Sclerosis Complex Patient and the Role of Mammalian Target of Rapamycin Inhibitor: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E
Transplant Proc; 2020 Oct; 52(8):2520-2523. PubMed ID: 32448667
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
5. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
6. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
[TBL] [Abstract][Full Text] [Related]
9. Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors.
Agricola K; Stires G; Krueger DA; Capal JK; Franz DN; Ritter DM
Pediatr Neurol; 2021 Jul; 120():7-10. PubMed ID: 33962348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
11. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
[TBL] [Abstract][Full Text] [Related]
15. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
16. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
[TBL] [Abstract][Full Text] [Related]
17. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
19. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
